![]() ![]() Per subject results were similar, where 88% of the treated subjects showed improvement in the appearance of cellulite in both thighs in dimples and/or undulation at 3 months follow up, and 86% of the treated subjects showed improvement at 6 months follow up. When considering improvement in each cellulite feature separately, 86% of the treated thighs (of the 80 thighs with dimples at baseline) showed improvement in dimples, and 76% of the thighs (all thighs had undulation at baseline) showed improvement in undulation irregularities. ![]() Sustained improvement was observed at six month follow up in 93% of the treated thighs. Food and Drug Administration (FDA) 510(k) clearance for Profound™ when using the SubQ handpiece and cartridge to improve the appearance of cellulite in patients with Fitzpatrick skin types I-III, as supported by long term data (6 months).Ī recent multi-center clinical study of Profound showed improvement of cellulite severity (in dimples and/undulation irregularities) in 94% of treated thighs assessed at a three month follow up by blinded review. Specifically, the 25º Dermal handpiece and cartridge are used for percutaneous treatment of facial wrinkles, and the 75º SubQ handpiece and cartridge are used to improve the appearance of cellulite in patients with Fitzpatrick skin types I-III as supported by long-term clinical data (6 months).įDA 510(K) CLEARANCE OF PROFOUND™ SUBQ TO IMPROVE THE APPEARANCE OF CELLULITE ![]() Profound™ is a minimally invasive, fractional radiofrequency (RF) microneedling device indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that it has achieved two major milestones to further strengthen Profound's position in the marketplace. 8, 2016/ PRNewswire / - Syneron Medical Ltd. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |